Hers vs Found: Platform Scope, Medication Sourcing, and Fit

You are reading a PlexusDx Education Hub comparison, part of our ongoing coverage of telehealth weight programs, GLP-1 science, and genetics. See the complete Peptides & GLP-1 library.

An independent editorial comparison. PlexusDx is not partnered with Hers or Found, receives no affiliate compensation, and has no commercial stake in either brand.

Full head-to-head: PlexusDx vs Found →

Hers and Found both live in the crowded GLP-1 telehealth market, but they were built for different jobs. Hers grew out of a broad, multi-condition digital-health platform; Found was designed around weight specifically. This comparison lines up how each is structured, where they converge on the actual medicine, how the cost is assembled, and the biological input neither one screens. As of April 2026.

Two different telehealth business models

The core contrast is scope. Hers, part of Hims & Hers Health, is a broad direct-to-consumer platform spanning many conditions, with weight loss as one track among several. Found is purpose-built around weight. Both deliver care virtually and can route prescriptions to retail or licensed compounding pharmacies, but they approach the patient from opposite ends — generalist breadth versus category focus.

Hers: a broad platform with a weight-loss track

Hers operates as subscription telehealth inside a larger multi-condition platform. Its weight program typically includes virtual clinical evaluation, provider-issued prescriptions, and either FDA-approved brand dispensing or compounded semaglutide and tirzepatide via licensed 503A pathways. Details sit on Hers's official website, which reflects the current program at the time you read it.

Found: a weight-focused subscription

Found concentrates on weight management as its central offering. The mechanics resemble the category norm — intake, clinician review, prescription, and ongoing follow-up — with fulfillment through a retail or compounding pharmacy. Current specifics are published on Found's official website.

Where the two overlap: the compound itself

Whatever the branding, both programs rest on the same pharmacology. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual agonist tirzepatide modulate appetite, satiety, and gastric emptying, and their evidence comes from trials like STEP (NEJM 2021), SURMOUNT (NEJM 2022), and SURMOUNT-OSA (NEJM 2024). The molecule, not the platform, drives the effect.

Reading the price tag on each program

Pricing across GLP-1 telehealth varies widely as of April 2026, with typical monthly totals spanning roughly $200 to $700+ once program fees, medication, and any compounded dispensing are counted. Hers and Found each publish specifics on their own sites. Rather than repeat numbers that may be stale, check each brand's pricing page directly before deciding.

The genetic variable no subscription reads

Here is the layer none of these telehealth workflows examine: the inherited biology that sets the stage before any GLP-1 molecule arrives. Markers in GLP1R — the biological target of the entire drug class — plus FTO and TCF7L2 outline the metabolic starting point that neither a broad platform nor a weight-only subscription checks. These are pathway-level markers. They do not predict how you will respond to any particular drug, but they describe the metabolic terrain a prescriber is writing into. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across that terrain, mapping appetite regulation, satiety, and energy-balance biology so a conversation with your own clinician starts from data rather than guesswork. It is not a pharmacogenomic test and never forecasts a medication's effect.

PlexusDx sits in the same category, offering semaglutide and tirzepatide via its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — but pairs the prescription with upstream genetic insight neither a broad platform nor a weight-only subscription typically includes.

Not affiliated: PlexusDx has no affiliation and no commercial relationship with Hers or the other programs discussed in this review.

Related reading on PlexusDx: GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1, GLP 1 What Is.

Educational review only. PlexusDx is not affiliated with Hers or Found and has no commercial tie to either. PlexusDx sells semaglutide and tirzepatide through its own Weight Management Protocols; this comparison weighs telehealth approaches. The Precision Peptide Genetic Test reads gene–pathway influence and predicts no medication outcome. Speak with a qualified healthcare provider before any peptide protocol.

Consider a third option: look at the PlexusDx Weight Management Protocols, or start with the Precision Peptide Genetic Test to map your metabolic profile before choosing any platform.

Frequently Asked Questions

Is Hers or Found better for weight loss?

Neither is objectively better. Hers offers weight care inside a broad multi-condition platform, while Found is weight-specific; the right fit depends on whether you value platform breadth or category focus, plus cost, coverage, and program mechanics. Review each brand's current details before deciding, since both can prescribe the same compounds.

Do Hers and Found use the same medications?

Both can prescribe GLP-1 receptor agonists like semaglutide and the dual agonist tirzepatide through telehealth. What differs is the dispensing pathway — FDA-approved brand versus compounded 503A — along with tiers and provider model. The pharmacology is set by the compound, not by which platform delivers it.

Which is cheaper, Hers or Found?

It depends on the medication, tier, and dispensing route, and both publish figures on their own sites. Across GLP-1 telehealth as of April 2026, monthly totals commonly run from roughly $200 to $700+. Compare current pricing pages directly rather than relying on a single quoted number.

Does the Precision Peptide Genetic Test replace either program?

No. It is not a treatment or a substitute for clinical care. The test maps pathway-level variants in genes such as GLP1R, FTO, and TCF7L2 that describe your baseline metabolism, giving you context to bring into a conversation with a provider — whichever program you ultimately consider.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.